There is a lot of talk about health care costs in the United States that is mostly centered on prescription medicine spending, overlooking the largest share of U.S. health care spending – hospital care. And hospital spending continues to grow as their prices increase.
Studies have shown hospitals mark up medicines up to 500% of their cost, with nearly one in five hospitals marking up medicine prices by 700% or more. But prescription medicines are just one piece of the hospital cost picture. Data recently featured by Axios point out how much more we spend on hospital care compared to retail prescription medicines.
Fact: The United States spends three times more per person on hospital care than on retail prescription medicines.
![Hospital Care Chart5[2]](https://cdn.aglty.io/phrma/global/blog/import/images/Hospital Care Chart5 2.jpg)
These data, coupled with a recent analysis from United Health Group, highlight how hospitals are the primary drivers of health care spending. United Health Group found that prices for inpatient care charged by hospitals increased significantly from 2013 to 2017, far surpassing prices paid to independent physicians for the same care. According to the analysis, hospital prices increased by 4.5% per year over this period while independent physician prices increased just 2.5%.
Rather than looking at one piece of the health care system, we need a robust discussion about the whole system and ways we can rein in health care spending. Looking at hospital costs is a critical place to start. Learn more at LetsTalkAboutCost.org.
Nicole Longo
Nicole Longo is Deputy Vice President of public affairs at PhRMA focusing on Medicare, 340B, importation and more. She previously worked for a D.C.-based public affairs firm where she assisted a wide range of clients with communications efforts on everything from trade policy to agriculture policy to health care policy. Outside the office, Nicole can be found trying new restaurants (usually Italian), taking an occasional barre class and cheering on the Cincinnati Bengals.
Nicole Longo
ICYMI: Hospital consolidation is driving up health care costs
340B’s reality: A booming business for hospitals, pharmacies and corporate giants
A program off track: How 340B drives both hospital consolidation and system gaming
Washington Post Editorial Board says 340B has become “corporate welfare”
Hospitals drive nearly 80% of the U.S. health spending gap
Congress should look under the hood of 340B, hospitals don't want them to
340B hospitals buy low and sell high, a new analysis shows
New report from Minnesota: 340B is generating billions for big hospitals
Latest analysis from Ohio exposes growing abuses of the 340B markup program
By the Numbers: 340B continues to climb in profits, dwindle with patient support
New report: Hospitals mark up medicine prices 500%
read more
Nonprofit hospitals fall short on community benefit, studies show
Why Congress should prioritize fixing the 340B program
What they are saying: Nonprofit hospitals are gaming the system at the expense of patients
340B program continues to drive shift in care to more expensive hospital settings
New analysis confirms hospitals markup prices for oncology therapies
340B 101: Three charts show the program maximizes hospitals’ bottom line with little consideration for patients
To drive up profits, hospitals continue unnecessary medicine mark-ups, burdening patients, employers and health care system
340B hospitals among those that provide lowest levels of community benefit across the country
New data from insurers show detriments of copay accumulator adjustment programs
Getting the 340B program back on track in 2021
Nearly 40% of commercially insured patients face half their annual out-of-pocket expenses from just one health care encounter
Insurers shift medicine costs to patients with severe chronic illnesses
The new Administration should reconsider a recent HHS rule that could negatively impact patient access and affordability
New insulin report highlights how incentives benefit middlemen, harm patients
New data show retail medicine prices fell in 2019
Correcting the record: Biopharmaceutical companies remain committed to the 340B program and helping patients
Accumulator adjustment programs lead to surprise out-of-pocket costs and nonadherence, analysis finds
340B hospitals and for-profit pharmacies generating significant revenue from program meant to help needy patients
Study finds biopharmaceutical innovation is responsible for 35% of the increase in life expectancy from 1990 to 2015
Survey found insurance premiums grew faster than inflation in 2020
Study finds middlemen excluded nearly 850 medicines from formularies this year
Manufacturer cost-sharing assistance programs can save chronically ill patients hundreds to thousands of dollars annually
Commercial health plans have increased patients’ out-of-pocket costs by over 50% in some therapeutic areas
Commercial health plans transition from copays to coinsurance and deductibles has increased patient out-of-pocket costs
Four things to know about the IQVIA “Medicine Spending and Affordability in the U.S.” report
New data show commercially insured patients face increasingly high cost sharing for brand medicines
Payers subject 80% of new RA and MS patients to utilization management restrictions
Study finds the pharmaceutical industry retains a smaller share of revenue than research-intensive industries
ICYMI: Pharmacy benefit managers increasingly exclude medicines from formularies, restricting patient access
New rule makes it harder for patients to lower their out-of-pocket costs
ICYMI: Patients saved nearly $800,000 out of pocket through innovative contracting arrangements
Retail medicine spending to remain stable share of overall health care spending through next decade
PhRMA comments on HHS proposed rule on manufacturer cost-sharing assistance and accumulator adjustment programs
Addressing barriers that inhibit value-based contracts
Fact Check: HCCI analysis overstates medicine spending and prices
Cancer medicines cost twice as much at hospitals, study finds
New GAO report: Some hospitals participating in 340B may not be eligible for the program
Nearly 50% of brand medicine spending goes to the supply chain and others
New NHE data: Medicine prices declined, and hospitals were biggest driver of health care spending in 2018
More evidence that medicine prices are growing at slowest rate in decades
The truth about the marketing and promotion of medicines
Survey shows out-of-pocket costs top health care concern for voters
Hospitals make 9 times more than physicians’ offices on provider-administered medicines
340B Spotlight: How for-profit middlemen are taking advantage of a program meant to support nonprofit entities and patients
Three things to know about the Part D GAO report
Four states adopt first-in-the-nation laws to protect patients from surprise insurer practices
New Let’s Talk About Cost TV ad asks: Why aren’t patients sharing in savings at the pharmacy counter?
Study finds hospitals continue to mark up medicines up to 500% of their cost
Three reasons why the latest Rx Savings Solutions analysis is misleading
How the rebate rule would help reduce patients’ out-of-pocket costs
Fresh data show, yet again, 340B is growing while charity care dwindles at many 340B hospitals
New study finds hospitals continue to push patients to costlier outpatient settings
4 Things to know about the IQVIA “Medicine Use and Spending” report
Six policy solutions to help patients afford their insulin
PhRMA comments on OIG proposed rule to reform the rebate system
340B continues to drive shift in site of care for physician-administered medicines to more expensive hospital settings
Five key facts about the market for insulins
OIG proposed rule could help strengthen the Part D market
Rebate rule would help ensure seniors with diabetes don’t pay more for their medicine than their insurer
The PBM story you haven’t heard: Hidden fees quadrupled in two years
OptumRX: Sharing rebates with patients is “worth it”
New data show how sharing negotiated discounts could save certain patients hundreds of dollars at the pharmacy counter
What you need to know about the new NHE health spending projections
New study shows why insurers should share rebates with Medicare Part D beneficiaries on a mandatory basis
New IQVIA data show medicine prices grew just 1.5 percent in 2018
Health Affairs study misses the mark on medicine costs
New government data show medicine price growth continues to decline
10 things you should know about medicine spending and costs
New study finds hospitals prescribe more medicines, and more expensive medicines, after joining 340B program
Six key facts about the market for insulins
Americans want to know more than just the list price of a medicine—and we’re answering their call
What they are saying: PhRMA member executives on industry’s new approach to DTC television advertising
Coupons allow patients to remain on medicines in spite of high cost sharing and deductibles
New study finds some hospitals mark up medicine prices at least 700 percent
69 percent of patients abandon medicines when cost sharing is more than $250
New analysis finds 340B medicine sales hit record high in 2017 and continue to grow as a share of total drug spending
New analysis in Health Affairs reinforces one-third of medicine list price rebated back to supply chain
PhRMA submission to HHS on blueprint to lower drug prices and reduce out-of-pocket costs
GAO again recommends improvements to 340B program
New data show patients’ out-of-pocket costs are rising faster than their insurers’ costs
Pass-through rebates do not violate non-interference clause but they do increase savings for seniors
Patients with a deductible have seen their out-of-pocket costs for brand medicines increase 50 percent since 2014
ICYMI: Analysis finds higher outpatient drug spending at 340B hospitals
Sharing negotiated discounts at the pharmacy counter could save seniors with diabetes more than $350 annually
New 340B analysis: Hospitals raking in billions while uncompensated care drops by billions
Video: PhRMA CEO discusses biopharmaceutical supply chain at POLITICO event
Event tomorrow: Making the biopharmaceutical supply chain work for patients
Spending on medicines grew less than one percent in 2017
Patients pay the price when hospitals mark up cancer medicines
340B Spotlight: How much money are hospitals pocketing under 340B and what are they doing with those profits?
New Let’s Talk About Cost ads highlight how copay accumulator programs could leave patients financially exposed
Video: How does the supply chain shape brand-name medicine prices?
4 Things to know about the IQVIA 2018 and Beyond: Outlook and Turning Points report
ICYMI: Two PBM reports show dramatic slowdown in medicine spending growth
Copay coupons can help ease patients’ out-of-pocket costs
340B Spotlight: Hospital system adds voice to comments about flawed 340B program
PhRMA launches new consumer-facing Let’s Talk About Cost website
340B Spotlight: New pieces of legislation continue momentum to fix 340B program
NHE Data: Medicine spending grew just 1.3 percent in 2016
340B Spotlight: ICYMI – 340B hearing, new reports highlight growing need for program reform
How much are hospitals marking up the price of medicines? The answer may surprise you.
4 things to know about the QuintilesIMS drivers of medicine spending in the U.S. report
Video: PhRMA CEO discusses medicine costs with CNBC's Squawk Box
340B Spotlight: New analysis finds 340B program growth continues to accelerate despite false claims
340B Spotlight: ICYMI – AJC looks at how some Georgia hospitals are profiting off 340B
340B Spotlight: 340B hospitals continue to benefit from consolidation at expense of patients
New analysis: More than half of patients’ out-of-pocket spending for brand medicines is based on full list price
340B Spotlight: Audit findings show importance of increased oversight of 340B program
Fact Check: How hospitals continue to drive health care spending
Hospitals
Lets Talk About Cost
Fact Check: How hospitals continue to drive health care spending
Fact Check: How hospitals continue to drive health care spending